Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Bio-Thera and Biogen Tocilizumab Phase 3 Switching Study

Sep 11, 2024

On 11 September 2024, Bio-Thera Solutions and Biogen published results from their phase 3 switching study for Tofidence™ (BAT1806/BIIB800), biosimilar to Roche’s Actemra®/RoActemra® (tocilizumab). The study showed that comparable clinical efficacy, safety,...

Approval Alert: Celltrion’s Biosimilar Ustekinumab Approved in AU

Sep 11, 2024

The Australian Therapeutic Goods Administration (TGA) has approved Celltrion’s SteQeyma® (CT-P43), biosimilar to Janssen’s Stelara® (ustekinumab).  SteQeyma is approved for a 130 mg/26 mL concentrate for solution for infusion vial to treat moderate to severe plaque...

Iconovo Commences Development of Intranasal Semaglutide

Sep 10, 2024

On 10 September 2024, Swedish CDMO, Iconovo, announced that it has commenced developing an intranasally inhaled form of semaglutide for treatment of obesity.  The product will reportedly use an improved form of Iconovo’s existing intranasal inhaler “ICOone Nasal®”....

Bayer’s High Dose Eylea™ (Aflibercept) PFS Approved in Europe

Sep 9, 2024

On 9 September 2024, Bayer announced that the European Medicines Agency (EMA) has approved its Eylea™ (aflibercept) 8mg pre-filled syringe (PFS), “OcuClick™”, for nAMD and diabetic macular oedema (DME).  Bayer reports that Germany will be one of the first launch...

BMS’ Opdivo® Funded for Kidney Cancer in NZ from 1 November 2024

Sep 9, 2024

New Zealand’s government drug funding agency Pharmac has announced that BMS’ Opdivo® (nivolumab) will be fully funded for eligible kidney patients from 1 November 2024. As previously reported, New Zealand has recently increased funding for cancer drugs, including...

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here